

Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

<https://marketpublishers.com/r/E396627EAB0EN.html>

Date: March 2017

Pages: 108

Price: US\$ 3,040.00 (Single User License)

ID: E396627EAB0EN

Abstracts

The Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Non-alcoholic Fatty Liver Disease (NAFLD) Drug market study provides comprehensive data which enhances the understanding, scope and application of this report.

This report provides comprehensive analysis of

Key market segments and sub-segments

Evolving market trends and dynamics

Changing supply and demand scenarios

Quantifying market opportunities through market sizing and market forecasting

Tracking current trends/opportunities/challenges

Competitive insights

Opportunity mapping in terms of technological breakthroughs

Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis by Countries:

Germany
France
UK
Russia
Italy
Spain
Benelux

The Major players reported in the market include:

Conatus Pharmaceuticals
Daewoong Pharmaceutical
Galmed International
Kyorin Pharmaceutical
Metabolic Solutions Development
Novartis AG
Phenex Pharmaceuticals
Raptor Pharmaceuticals
TCM Biotech International

Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis by Product:

Type 1
Type 2
Type 3

Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis by

Application:

Application 1
Application 2
Application 3

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Contents

Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Report Forecast 2017-2021

1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET OVERVIEW

1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

1.2 Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

1.2.1 Type

1.2.2 Type

1.2.3 Type

1.3 Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

1.3.2 Application

1.3.3 Application

1.3.4 Application

1.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market States Status and Prospect (2012-2021) by Countries

1.4.1 Germany

1.4.2 France

1.4.3 UK

1.4.4 Russia

1.4.5 Italy

1.4.6 Spain

1.4.7 Benelux

1.5 Europe Market Size (Value and Volume) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2012-2021)

1.5.1 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2021)

1.5.2 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)

2 EUROPE ECONOMIC IMPACT ON NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG INDUSTRY

2.1 Europe Macroeconomic Analysis

2.2 Europe Macroeconomic Environment Development Trend

3 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MANUFACTURING

COST ANALYSIS

3.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis

3.1.1 Key Raw Materials

3.1.2 Price Trend of Key Raw Materials

3.1.3 Key Suppliers of Raw Materials

3.1.4 Market Concentration Rate of Raw Materials

3.2 Proportion of Manufacturing Cost Structure

3.2.1 Raw Materials

3.2.2 Labor Cost

3.2.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

4 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

4.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis

4.2 Upstream Raw Materials Sourcing

4.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015

4.4 Downstream Buyers

5 EUROPE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET ANALYSIS BY MANUFACTURERS, TYPE AND APPLICATION

5.1 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competition by Manufacturers

5.1.1 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share of Key Manufacturers (2015 and 2016)

5.1.2 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufacturers (2015 and 2016)

5.2 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug (Volume and Value) by Type

5.2.1 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type (2012-2017)

5.2.2 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)

5.3 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug (Volume and Value) by Countries

5.3.1 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market

Share by Countries (2012-2017)

5.3.2 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Countries (2012-2017)

5.4 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug (Volume) by Application

6 GERMANY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

6.1 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

6.1.1 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

6.1.2 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

6.1.3 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

6.2 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

6.3 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

6.4 Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

7 FRANCE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

7.1 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

7.1.1 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

7.1.2 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

7.1.3 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

7.2 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

7.3 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

7.4 France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by

Application

8 UK NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

8.1 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

8.1.1 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

8.1.2 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

8.1.3 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

8.2 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

8.3 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

8.4 UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

9 RUSSIA NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

9.1 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

9.1.1 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

9.1.2 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

9.1.3 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

9.2 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

9.3 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

9.4 Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

10 ITALY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

10.1 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

10.1.1 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

10.1.2 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

10.1.3 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

10.2 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

10.3 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

10.4 Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

11 SPAIN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

11.1 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

11.1.1 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

11.1.2 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

11.1.3 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

11.2 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

11.3 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

11.4 Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

12 BENELUX NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG (VOLUME, VALUE AND SALES PRICE)

12.1 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Value (2012-2017)

12.1.1 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

12.1.2 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

12.1.3 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

12.2 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Manufacturers

12.3 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type

12.4 Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application

13 EUROPE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MANUFACTURERS ANALYSIS

13.1 Conatus Pharmaceuticals

13.1.1 Company Basic Information, Manufacturing Base and Competitors

13.1.2 Product Type, Application and Specification

13.1.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.1.4 Business Overview

13.2 Daewoong Pharmaceutical

13.2.1 Company Basic Information, Manufacturing Base and Competitors

13.2.2 Product Type, Application and Specification

13.2.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.2.4 Business Overview

13.3 Galmed International

13.3.1 Company Basic Information, Manufacturing Base and Competitors

13.3.2 Product Type, Application and Specification

13.3.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.3.4 Business Overview

13.4 Kyorin Pharmaceutical

13.4.1 Company Basic Information, Manufacturing Base and Competitors

13.4.2 Product Type, Application and Specification

13.4.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.4.4 Business Overview

13.5 Metabolic Solutions Development

13.5.1 Company Basic Information, Manufacturing Base and Competitors

13.5.2 Product Type, Application and Specification

13.5.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.5.4 Business Overview

13.6 Novartis AG

13.6.1 Company Basic Information, Manufacturing Base and Competitors

13.6.2 Product Type, Application and Specification

13.6.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.6.4 Business Overview

13.7 Phenex Pharmaceuticals

13.7.1 Company Basic Information, Manufacturing Base and Competitors

13.7.2 Product Type, Application and Specification

13.7.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.7.4 Business Overview

13.8 Raptor Pharmaceuticals

13.8.1 Company Basic Information, Manufacturing Base and Competitors

13.8.2 Product Type, Application and Specification

13.8.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.8.4 Business Overview

13.9 TCM Biotech International

13.9.1 Company Basic Information, Manufacturing Base and Competitors

13.9.2 Product Type, Application and Specification

13.9.3 Production, Revenue, Price and Gross Margin (2012-2017)

13.9.4 Business Overview

13 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

13.1 Marketing Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Development Trend

13.2 Market Positioning

13.2.1 Pricing Strategy

13.2.2 Brand Strategy

13.2.3 Target Client

13.3 Distributors/Traders List

14 MARKET EFFECT FACTORS ANALYSIS

14.1 Technology Progress/Risk

14.1.1 Substitutes Threat

- 14.1.2 Technology Progress in Related Industry
- 14.2 Consumer Needs/Customer Preference Change
- 14.3 Economic/Political Environmental Change

15 EUROPE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET FORECAST (2017-2021)

- 15.1 Germany Market Forecast (2017-2021)
- 15.2 France Market Forecast (2017-2021)
- 15.3 UK Market Forecast (2017-2021)
- 15.4 Russia Market Forecast (2017-2021)
- 15.5 Italy Market Forecast (2017-2021)
- 15.6 Spain Market Forecast (2017-2021)
- 15.7 Benelux Market Forecast (2017-2021)
- 15.8 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast by Type (2017-2021)
- 15.9 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast by Application (2017-2021)

16 APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Table Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Europe Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015
Table Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Europe Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Application in 2015
Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Figure Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2021)
Figure Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2021)
Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales of Key Manufacturers (2015 and 2016)
Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Figure 2016 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue by Manufacturers (2015 and 2016)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers (2015 and 2016)

Table 2015 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers

Table 2016 Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Type (2012-2017)

Figure Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type (2012-2017)

Figure Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type (2012-2017)

Figure Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Growth Rate by Type (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Countries (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Countries (2012-2017)

Figure Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Countries (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Countries (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Countries (2012-2017)

Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Countries (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application (2012-2017)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Application (2012-2017)

Figure Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by

Application (2012-2017)

Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend

(2012-2017)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2017)

Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2017)

Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Price Trend (2012-2017)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Manufacturers (2015 and 2016)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Manufacturers (2015 and 2016)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2015 and 2016)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Type (2015 and 2016)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2015 and 2016)

Table Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share by Application (2015 and 2016)

Table Conatus Pharmaceuticals Basic Information List

Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Daewoong Pharmaceutical Basic Information List

Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Galmed International Basic Information List

Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Kyorin Pharmaceutical Basic Information List

Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Metabolic Solutions Development Basic Information List

Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Novartis AG Basic Information List

Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market

Share (2012-2017)

Table Phenex Pharmaceuticals Basic Information List

Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Figure Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table Raptor Pharmaceuticals Basic Information List

Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)

Table TCM Biotech International Basic Information List

Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)

Figure TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017).

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis

Table Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015

Table Major Buyers of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Table Distributors/Traders List

Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure Germany Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure France Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure UK Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate

Forecast (2017-2021)

Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure Russia Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure Italy Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure Spain Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate Forecast (2017-2021)

Figure Benelux Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Type (2017-2021)

Table Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Application (2017-2021)

COMPANIES MENTIONED

Conatus Pharmaceuticals, Daewoong Pharmaceutical, Galmed International, Kyorin Pharmaceutical, Metabolic Solutions Development, Novartis AG, Phenex Pharmaceuticals, Raptor Pharmaceuticals, TCM Biotech International, Tobira Therapeutics, Verva Pharmaceuticals, Zafgen

I would like to order

Product name: Europe Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report
Forecast 2017-2021

Product link: <https://marketpublishers.com/r/E396627EAB0EN.html>

Price: US\$ 3,040.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/E396627EAB0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

